

NOVO NORDISK A S
Form 6-K
November 29, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

November 29, 2010

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Company Announcement

29 November 2010

Novo Nordisk A/S – Share repurchase programme

On 27 October 2010 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.4 billion in the period from 27 October 2010 to 23 December 2010.

Since the announcement as of 22 November 2010, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	970,000		542,920,957
22 November 2010	50,000	572.6800	28,634,000
23 November 2010	40,000	573.8900	22,955,600
24 November 2010	50,000	577.1700	28,858,500
25 November 2010	50,000	577.4500	28,872,500
26 November 2010	50,000	575.9800	28,799,000
Accumulated under the programme	1,210,000		681,040,557

With the transactions stated above, Novo Nordisk owns a total of 27,785,155 treasury shares, corresponding to 4.6% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

Company Announcement no 65 / 2010

Page 1 of 2

Novo Nordisk A/S	Novo Allé	Telephone:	Internet:	CVR no:
Investor Relations	2880 Bagsværd	+45 4444 8888	novonordisk.com	24256790
	Denmark	Telefax:		
		+45 4444 6626		

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,890 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media:

Anne Margrethe Hauge

Tel: (+45) 4442 3450

amhg@novonordisk.com

Investors:

Klaus Bülow Davidsen

Tel: (+45) 4442 3176

klda@novonordisk.com

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

krop@novonordisk.com

Jannick Lindegaard

Tel: (+45) 4442 4765

jlis@novonordisk.com

In North America:

Lori Moore

Tel: (+1) 609 919 7991

lrm@novonordisk.com

In North America:

Hans Rommer

Tel: (+1) 609 919 7937

hrrmm@novonordisk.com

Company Announcement no 65 / 2010

Page 2 of 2

Novo Nordisk A/S Novo Allé

Telephone:

Internet:

CVR no:

Investor Relations 2880 Bagsværd

+45 4444 8888

novonordisk.com

24256790

Denmark

Telefax:

+45 4444 6626

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: November 29, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer
